Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Real ‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
ConclusionsOur real-world survival analysis suggests that while AA plus prednisone may demonstrate comparable treatment efficacy to Enz in the context of nmCRPC, there may be an increased risk of non-cancer-caused death. Physicians should take into consideration this information when making treatment decisions for patients with nmCRPC. (Source: Cancer Medicine)
Source: Cancer Medicine - September 14, 2023 Category: Cancer & Oncology Authors: Takuya Tsujino,
Satoshi Tokushige,
Kazumasa Komura,
Wataru Fukuokaya,
Takahiro Adachi,
Yosuke Hirasawa,
Takeshi Hashimoto,
Atsuhiko Yoshizawa,
Masanobu Saruta,
Takaya Ohno,
Keita Nakamori,
Ryoichi Maenosono,
Kazuki Nishimura,
Shogo Yamazaki, Tags: RESEARCH ARTICLE Source Type: research
Efficacy and Safety of PARP inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Clinical Trials
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths among men in the United States, with an estimated 288,300 new cases and 34,700 deaths in 2023 [1]. Over the last decade, the landscape of treatments has changed significantly with the approval of several agents that improve overall survival in patients with metastatic prostate cancer, including androgen-receptor signaling inhibitors (ARSI) (abiraterone acetate [2], enzalutamide [3], apalutamide [4], and darolutamide [5]), and radioligand therapies (radium-223 [6] and 177Lu-PSMA-617 [7]). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 8, 2023 Category: Cancer & Oncology Authors: Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, Hyoyoung Choo-Wosoba, Gisela Butera, Mario Roselli, James L. Gulley, Fatima Karzai Tags: Anti-tumour Treatment Source Type: research
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128 (Source: Cancer Control)
Source: Cancer Control - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
CONCLUSIONS: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.PMID:37668202 | DOI:10.4111/icu.20230128 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dongdeuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Hyo Jin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok Joong Yun Jin Seon Cho See Min Choi Source Type: research
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & amp; therapeutics
Front Oncol. 2023 Aug 17;13:1193736. doi: 10.3389/fonc.2023.1193736. eCollection 2023.ABSTRACTProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate th...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Neha Thakur Sameer Quazi Bindu Naik Saurabh Kumar Jha Pallavi Singh Source Type: research
A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer
CONCLUSION: In Asian mHSPC patients, upfront ABI + ADT was associated with better PFS than DOC + ADT, with no significant OS difference. PSA kinetics may help stratify the prognosis for treatment intensification. Toxicity profiles were different, with a higher rate of toxicity-related treatment discontinuation in the DOC group.PMID:37604745 | DOI:10.1016/j.clgc.2023.07.012 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Benjamin H W Lam Vivian H M Tsang M P Lee Kuen Chan Tsz Chim Liu Brian Y H Ng Barry B W Wo K C Leung Wing Ho Mui Tim Wai Chan Martin Ho Ching Lam Steven W K Siu Darren M C Poon Source Type: research
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
Prostate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate the growth of prostate cancer cells. Further, PI3K/AKT/mTOR pathways interact with AR signaling ...
Source: Frontiers in Oncology - August 17, 2023 Category: Cancer & Oncology Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: AAP + C was safe with improved rPFS, OS duration, and a higher proportion of PSA declines. This suggests that AAP + C given earlier rather than sequentially may benefit some men. Further work is needed to identify this population.PMID:37582240 | DOI:10.1200/JCO.22.02639 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Susan F Slovin Karen Knudsen Susan Halabi Renee de Leeuw Ayesha Shafi Praneet Kang Steven Wolf Bin Luo Anuradha Gopalan Tracy Curley Mark Fleming Ana Molina Celina Fernandez Kevin Kelly Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
